Literature DB >> 8608863

Haploinsufficiency of parathyroid hormone-related peptide (PTHrP) results in abnormal postnatal bone development.

N Amizuka1, A C Karaplis, J E Henderson, H Warshawsky, M L Lipman, Y Matsuki, S Ejiri, M Tanaka, N Izumi, H Ozawa, D Goltzman.   

Abstract

Although apparently phenotypically normal at birth, mice heterozygous for inactivation of the gene encoding parathyroid hormone-related peptide (PTHrP) develop haplotype insufficiency by 3 months of age. In addition to histologic and morphologic abnormalities similar to those seen in homozygous mutants, heterozygous animals demonstrated alterations in trabecular bone and bone marrow. These included metaphyseal bone spicules which were diminished in volume, irregularly distributed, and less well developed than those seen in age-matched controls as well as bone marrow, which contained an inordinate number of adipocytes. A substantial reduction in PTHrP mRNA was detected in heterozygous tissue, while circulating parathyroid hormone (PTH) and calcium concentrations were normal. Thus, while a physiologic concentration of PTH was capable of maintaining calcium homeostasis, it was incapable of compensating for PTHrP haploinsufficiency in developing bone. In normal animals, both PTHrP and the PTH/PTHrP receptor were expressed predominantly in chondrocytes situated throughout the proliferative zone of the tibial growth plate. In the metaphysis, the PTH/PTHrP receptor was identified on osteoblasts and preosteoblastic cells situated in the bone marrow, while PTHrP was expressed only by osteoblasts. These observations indicate that postnatal bone development involves susceptible pathways that display exquisite sensitivity to critical levels of PTHrP and imply that the skeletal effects of PTH are influenced by locally produced PTHrP. Moreover, identification of both the ligand and its N-terminal receptor in metaphyseal osteoblasts and their progenitors suggests an autocrine/paracrine role for the protein in osteoblast differentiation and/or function. Impairment in this function as a consequence of PTHrP haploinsufficiency may critically influence the course of bone formation, resulting in altered trabecular architecture and perhaps low bone mass and increased bone fragility.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8608863     DOI: 10.1006/dbio.1996.0104

Source DB:  PubMed          Journal:  Dev Biol        ISSN: 0012-1606            Impact factor:   3.582


  47 in total

Review 1.  PTH and PTHrP effects on the skeleton.

Authors:  A C Karaplis; D Goltzman
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

2.  Local and systemic control of the osteoblast.

Authors:  G J Strewler
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

Review 3.  Osteoblastogenesis regulation signals in bone remodeling.

Authors:  C Zuo; Y Huang; R Bajis; M Sahih; Y-P Li; K Dai; X Zhang
Journal:  Osteoporos Int       Date:  2012-06       Impact factor: 4.507

4.  Safety and tolerability of subcutaneous PTHrP(1-36) in healthy human volunteers: a dose escalation study.

Authors:  Mara J Horwitz; Mary Beth Tedesco; Susan M Sereika; Adolfo Garcia-Ocaña; Alessandro Bisello; Bruce W Hollis; Caren Gundberg; Andrew F Stewart
Journal:  Osteoporos Int       Date:  2005-09-07       Impact factor: 4.507

Review 5.  Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis.

Authors:  T J Martin; N A Sims; K W Ng
Journal:  Osteoporos Int       Date:  2008-03-13       Impact factor: 4.507

Review 6.  Genetics of osteoporosis from genome-wide association studies: advances and challenges.

Authors:  J Brent Richards; Hou-Feng Zheng; Tim D Spector
Journal:  Nat Rev Genet       Date:  2012-07-18       Impact factor: 53.242

7.  Research resource: Haploinsufficiency of receptor activity-modifying protein-2 (RAMP2) causes reduced fertility, hyperprolactinemia, skeletal abnormalities, and endocrine dysfunction in mice.

Authors:  Mahita Kadmiel; Kimberly Fritz-Six; Suruchi Pacharne; Gareth O Richards; Manyu Li; Tim M Skerry; Kathleen M Caron
Journal:  Mol Endocrinol       Date:  2011-05-12

8.  Loss of Gsα early in the osteoblast lineage favors adipogenic differentiation of mesenchymal progenitors and committed osteoblast precursors.

Authors:  Partha Sinha; Piia Aarnisalo; Rhiannon Chubb; Noriaki Ono; Keertik Fulzele; Martin Selig; Hamid Saeed; Min Chen; Lee S Weinstein; Paola Divieti Pajevic; Henry M Kronenberg; Joy Y Wu
Journal:  J Bone Miner Res       Date:  2014-11       Impact factor: 6.741

Review 9.  Understanding and targeting osteoclastic activity in prostate cancer bone metastases.

Authors:  J L Sottnik; E T Keller
Journal:  Curr Mol Med       Date:  2013-05       Impact factor: 2.222

10.  The N- and C-terminal domains of parathyroid hormone-related protein affect differently the osteogenic and adipogenic potential of human mesenchymal stem cells.

Authors:  Antonio Casado-Diaz; Raquel Santiago-Mora; José Manuel Quesada
Journal:  Exp Mol Med       Date:  2010-02-28       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.